Topic: Zuranolone

Major depressive disorder is a debilitating neurodegenerative disorder which afflicts approximately 14-20% of the general population; of those individuals, approximately 30% are treatment resistant to antidepressant medications. Recently, the FDA has approved a novel antidepressant, Zuranolone for use in individuals who suffer from postpartum depression and, this drug has shown very promising results. Using 488uM thick hippocampal brain slices, local field potential (LFP) recordings were conducted and analyzed for changes in sharp wave ripple (SWR) complexes. In order to assess in-vivo changes